Current Prices from ProKidney Corp. - Class A Ordinary Shares

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	PROK	USD	06.06.2025 23:44	0,94 USD	0,78 USD +21,11 %

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
0,00 %	24,50 %	36,57 %	-10,02 %	-54,14 %	-73,76 %	-90,65 %

Company Profile for ProKidney Corp. - Class A Ordinary Shares Share

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Company Data

Name ProKidney Corp. - Class A Ordinary Shares

Company ProKidney Corp.

Symbol PROK

Website https://www.prokidney.com

Primary Exchange

NASDAQ

ISIN KYG7S53R1049

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Dr. Bruce Culleton M.D.

Market Capitalization 216 Mio

Country United States of America

Currency USD

Employees 0,2 T

Address 2000 Frontis Plaza Blvd., 27103 Winston-Salem

IPO Date 2021-06-30

ID Changes

Date	From	To
12.07.2022	DNAC	PROK

Ticker Symbols

Name	Symbol
NASDAQ	PROK

More Shares

Investors who ProKidney Corp. - Class A Ordinary Shares hold also have the following shares in their portfolio:

Silynxcom Ltd. Ordinary Shares Share

USD/MMK MYANMARISCHER KYAT Currency

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog